Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

MediBeacon gets FDA approval for next-gen kidney function monitoring system

INNOVATE Corp. (NYSE:VATE) said MediBeacon, in which it holds a 44.7% equity stake, has received U.S. Food and Drug Administration approval for its next-generation MediBeacon TGFR System, introducing a reusable sensor intended to broaden access to point-of-care kidney function assessment.

Leia mais: MediBeacon gets FDA approval for next-gen kidney function monitoring system
Grafa

Cardone Ventures makes unsolicited $89M proposal to acquire PetMed Express

Cardone Ventures, the investment firm led by billionaire Grant Cardone and business partners Brandon and Natalie Dawson, has made an unsolicited, non-binding proposal to acquire PetMed Express (NASDAQ:PETS) for $4.25 per share in cash, implying an equity value of around $89 million.

Leia mais: Cardone Ventures makes unsolicited $89M proposal to acquire PetMed Express
Grafa
Health

Monte Rosa’s MRT-2359 combination shows striking activity in AR-mutant mCRPC subgroup

Monte Rosa Therapeutics (NASDAQ:GLUE) reported encouraging early clinical results for its molecular glue degrader MRT-2359 in combination with enzalutamide, showing pronounced activity in a genetically defined subset of heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).

Leia mais: Monte Rosa’s MRT-2359 combination shows striking activity in AR-mutant mCRPC subgroup
Grafa
Technology

Corteva and Hexagon Bio form JV to fast-track nature-derived crop protection

Corteva (NYSE:CTVA), the agricultural technology giant, and Hexagon Bio, a biotechnology company focused on nature-derived therapeutics, announced a multi-million-dollar joint venture aimed at accelerating the discovery of new crop protection solutions.

Leia mais: Corteva and Hexagon Bio form JV to fast-track nature-derived crop protection
Grafa
Health

Cosette Pharma wins FDA approval for first generic CIPRO HC with 180-day exclusivity

Cosette Pharmaceuticals said the U.S. Food and Drug Administration has approved its abbreviated new drug application for the first generic version of CIPRO HC, granting the company 180 days of Competitive Generic Therapy exclusivity and ending a more than 27-year stretch without a generic alternative.

Leia mais: Cosette Pharma wins FDA approval for first generic CIPRO HC with 180-day exclusivity